🇺🇸 BMS-986278 in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 5
Most-reported reactions
- Cystitis — 1 report (20%)
- Haematuria — 1 report (20%)
- Idiopathic Pulmonary Fibrosis — 1 report (20%)
- Lower Urinary Tract Symptoms — 1 report (20%)
- Urinary Tract Infection — 1 report (20%)
Other Immunology approved in United States
Frequently asked questions
Is BMS-986278 approved in United States?
BMS-986278 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for BMS-986278 in United States?
Bristol-Myers Squibb is the originator. The local marketing authorisation holder may differ — check the official source linked above.